Winton Group’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Winton Group’s Portfolio ZYBT Stock Details ZYBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.62K	Sell	12,730 -20,659	-62%	-$18.5K	﹤0.01%	1137
2026 Q1	$31.2K	Sell	33,389 -29,908	-47%	-$28K	﹤0.01%	1075
2025 Q4	$72.8K	Buy	63,297 +41,750	+194%	+$92.5K	﹤0.01%	888
2025 Q3	$56.5K	Buy	+21,547	New	+$149K	﹤0.01%	696

Other funds holding ZYBT

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Winton Group's ZYBT Position: Q2 2026 in Review

Winton Group reduced its Zhengye Biotechnology Holding (ZYBT) stake by 62% in Q2 2026, selling an estimated $18.5K and leaving 12,730 shares worth $8.62K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Winton Group first reported a position in ZYBT in Q3 2025 and has held it in 4 quarters since. The position peaked at $72.8K in Q4 2025. 4 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

Winton Group held 12,730 shares of Zhengye Biotechnology Holding worth $8.62K as of Q2 2026.
Winton Group sold 20,659 Zhengye Biotechnology Holding shares in Q2 2026, an estimated $18.5K.
Zhengye Biotechnology Holding made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1137 holding.
Winton Group first reported a position in Zhengye Biotechnology Holding in Q3 2025 and has held it in 4 quarters since.
Winton Group's Zhengye Biotechnology Holding position peaked at $72.8K in Q4 2025.
4 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.